Monthly Archives: December 2011

2012: A Critical Year for Biotechnology

Capitol

In 2012, we must continue to look for ways to reduce risk; enhance reward; reduce uncertainty; and reinforce the position of the industry as a major contributor resolving society’s most pressing needs. Policies to encourage investment in innovation and to speed discovery to scientific breakthroughs simply must be the priority in 2012. The industry relies on a policy and regulatory environment that encourages innovation for much needed treatments and cures for some of the most Read More >

Public Policy  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Biomedical Innovation: How the U.S. Can Stay Number One

lab_tech02-thumb

By Ross DeVol, chief research officer of the Milken Institute “The first step in winning the future is encouraging American innovation,” declared President Obama in his last State of the Union speech. A logical place to start is making sure that where we hold a lead, we keep it. Today, the U.S. has such a lead in biomedical innovation — the process of transforming scientific discoveries into vaccines, diagnostics, devices and therapies that improve and Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Biotech is a Cornerstone of New Orleans’ Economic Renaissance

New Orleans BioInnovation Center

New Orleans shows the signs of a city reborn from the destruction brought on by Hurricane Katrina.  The changes in the city’s infrastructure and building projects have certainly been among them.  The Crescent City reached a milestone in its renaissance last June when the New Orleans BioInnovation Center opened for business. The center is a 65,000-square foot biotech business incubator created to foster entrepreneurship within the New Orleans bioscience community and help commercialize technologies developed at Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Where’s the Deal?

2011-drug-deals-thumb

With only two weeks to go in 2011 it is looking like a five year low for deals. The chart below shows therapeutic deals dropping every year since 2007. We use the Windhover/Elsevier Strategic Transaction Database as our starting point for deal analytics. We analyze each deal to determine if the deal is for a drug asset, removing generic/OTC deals, manufacturing/service deals, device/diagnostics/tools deals, and tech transfer deals. What remains are deals for biotech company Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO CEO Company Snapshot: NuPathe Inc.

NuPathe

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February.  The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. For our first Snapshot for the BIO CEO event, we’ve spoken with NuPathe Inc. about their Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,